Preclinical Toxicity Evaluation of a Potent Oncolytic VirusOncolytic viruses (OV) represent a relatively new therapeutic paradigm that employs the ability of viruses toinfect tumor cells, multiply in them, destroy them and spread to other tumor cells in successive rounds.Over the last decade, a first wave of oncolytic viruses have been tested in the clinical realm, including OVsbased on herpes simplex virus Type 1 (HSV-1). These clinical trials have not showed evidence of doselimitingtoxicities in humans when injected directly into malignant gliomas or into brain surrounding theglioma, but evidence for efficacy in these small scale trials has also been lacking, probably due to their highdegree of attenuation. We have now developed and published preclinical efficacy results on a new, morepotent oncolytic virus (rQNestin34.5) that employs the human nestin promoter-enhancer element to driveexpression of the HSV1 gene, Y134.5, encoding the viral protein ICP34.5. This strategy allows the virus toreplicate to high yields in cells that express nestin, while replication in cells that do not express nestin isseverely attenuated. We and others have shown that nestin is expressed in a large proportion of gliomas,while it is not expressed in normal adult brain. In fact, nestin is one of the markers reported to distinguish theglioma 'stem-like' or 'initiator' subpopulation thought to provide the self-renewal capabilities of these tumors.In addition, we have published that immunomodulation with cyclophosphamide further enhances the potencyand antiglioma efficacy of rQNestin34.5. Therefore, at this juncture, our published efficacy studies, revealingimpressive and significant antiglioma properties of this OV, encourage us to pursue preclinical toxicitystudies in mice models of HSV1 toxicity (and non-human primate models) using preclinical lots of OV. Wethus propose the following four specific aim/milestones to justify two future clinical trials in humans:Milestone/Aim 1: Bioequivalency of rQNestin34.5v.2 and of reagents and standard operatingprotocol for future clinical grade production; Milestone/Aim 2: Validation of therapeutic efficacy andsafety monitoring with rQNestin34.5v.2; Milestone/Aim 3: Validation of safety monitoring withrQNestin34.5v.2 in presence of CPA: Milestone/Aim 4: Final toxicology/biodistribution study withGMP-grade clinical lot . The successful pursuit of milestone 4 will permit us to approach regulatoryagencies to start a phase I trial in patients with recurrent malignant glioma using rQNestin34.5v.2 + CPAimmomunodulation and subsequently a phase I trial in newly diagnosed glioma using rQNestin34.5v.2 +CPA immomunodulation + standard therapy.

Public Health Relevance

Malignant glioma remains a daunting challenge with minimal progress in the last 40 years in extendingpatient survival and time to tumor progression. The project will permit the development of a promisingbiologic agent as a new treatment for this cancer and allow its testing in human clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01NS061811-01A1
Application #
7696221
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
2008-09-30
Project End
2013-08-31
Budget Start
2008-09-30
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
$505,005
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kaufmann, Johanna K; Chiocca, E Antonio (2014) Glioma virus therapies between bench and bedside. Neuro Oncol 16:334-51
Price, Richard Lee; Chiocca, Ennio Antonio (2014) Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. Neurosurgery 61 Suppl 1:74-83
Chiocca, E Antonio; Rabkin, Samuel D (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295-300
Okemoto, Kazuo; Kasai, Kazue; Wagner, Benjamin et al. (2013) DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clin Cancer Res 19:5952-9
Kaur, Balveen; Chiocca, E Antonio; Cripe, Timothy P (2012) Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 13:1842-51
Gatson, NaTosha N; Chiocca, E Antonio; Kaur, Balveen (2012) Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett 527:62-70
Price, Richard L; Bingmer, Katherine; Harkins, Lualhati et al. (2012) Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/- mice. Cancer Res 72:5669-74
Alvarez-Breckenridge, Christopher A; Yu, Jianhua; Price, Richard et al. (2012) The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol 86:4566-77
Alvarez-Breckenridge, Christopher A; Yu, Jianhua; Price, Richard et al. (2012) NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 18:1827-34
Nakashima, Hiroshi; Kaur, Balveen; Chiocca, E A (2010) Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev 21:119-26

Showing the most recent 10 out of 13 publications